Job description
ROLE SUMMARY Since PAXLOVID's emergency use authorization on 12/22/21, PAXLOVID has helped treat over 25M patients at high-risk from progression to severe COVID-19, which can lead to hospitalization and/or death. PAXLOVID is well-positioned to remain the gold standard in COVID-19 treatment, despite competitive entry expected in 2026. Significant opportunity to increase treatment rates for eligible patients and bolster PAXLOVID's leadership position in the marketplace continues, as new burden of…